Gilead Sciences (NASDAQ:GILD) announced its Q4 financial results on Tuesday afternoon. While the company ended up beating revenue expectations, Gilead's results were a little disappointing when it came to its earnings.

The biotech giant reported fourth-quarter revenues of $5.88 billion, which is a 1% increase from last year, while earnings-per-share fell to $1.30 per share in comparison to the $1.44 reported in Q4 2018, or a 9.8% decline. Although Gilead outperformed on the $5.7 billion revenue target analysts were expecting, the biotech giant fell significantly short of the $1.67 EPS target Wall Street was anticipating.

Multiple financial statements with a fountain pen and a pair of glasses.

Image source: Getty Images.

Gilead's HIV pill, Biktarvy, remains the company's top-selling product. The drug brought in $1.57 billion in revenue for the quarter, a substantial increase from the $578 million reported in Q4 2018. The company's second and third top-selling products, two other HIV treatments known as Genvoya and Truvada, saw revenues of $958 million and $768 million respectively. In comparison to last year, however, both drugs have seen their revenue figures fall off a bit, with Genvoya reporting a 20.6% decline in revenue while Truvada saw a 6.7% decline over the same period.

Further details

Some of the company's smaller drugs have also seen solid revenue growth as well. Yescarta, an immunotherapy treatment used to treat B-cell lymphoma (lymph node cancer), generated $122 million in sales during Q4 2019, a 50% increase from the $81 million reported a year ago. 

Gilead is also one of many biotech companies working to develop a possible coronavirus vaccine. The company's Ebola drug, remdesivir, has shown some promise in reducing symptoms in patients with the condition.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.